A landmark study in China covering 42,703 families affected by rare diseases across 32 provincial regions of China has established a new diagnosis framework for rare diseases. It offers new hope to millions of patients struggling with delayed or incorrect diagnoses.

Too little snowfall is now also shaking the foundations of some of the world’s most resilient 'water towers', a new study led by the Pellicciotti group at the Institute of Science and Technology Austria (ISTA) shows. After establishing a monitoring network on a new benchmark glacier in central Tajikistan, the international team of researchers was able to model the entire catchment’s behavior from 1999 to 2023. The results, showing decreasing glacier health, were published in Communications Earth & Environment.

The study reveals that Migrion, a chimeric structure of virus and migrasome as an unprecedented unit of viral transmission that integrates viral dissemination with cell migration, providing fresh perspectives on infection dynamics.

A groundbreaking Genomic Press interview with Professor Gregor Hasler explores revolutionary psychedelic research reshaping psychiatric treatment globally. The Swiss neuroscientist discusses how substances like psilocybin and MDMA rapidly enhance neuroplasticity, offering lasting relief for depression, PTSD, and addiction where conventional treatments fail. His pioneering work on glutamate and GABA neurotransmitter systems establishes new therapeutic pathways that could transform mental healthcare for millions suffering from treatment-resistant conditions worldwide.

A new Genomic Press interview explores Professor Siegfried Kasper's transformative contributions to modern psychiatry and treatment-resistant depression research. The Austrian psychiatrist, with over 800 publications and an H-index of 131, discusses his pioneering work demonstrating the biological basis of psychiatric disorders and revolutionizing treatments including SSRIs and intranasal esketamine. His research has fundamentally changed how the international medical community approaches depression, schizophrenia, and anxiety disorders.